Uncategorized

Anti-competitive tactics by bad actors restrict access to generic and biosimilar drugs and drive up drug costs for consumers

WASHINGTON, DC] – Today U.S. Senators Richard Blumenthal (D-CT) and John Cornyn (R-TX) introduced the Affordable Prescriptions for Patients Actto help lower drug prices by preventing bad actors in the pharmaceutical industry from deliberately abusing the patent system. The bipartisan legislation would curb drug companies’ anti-competitive use of patents to prevent generic and biosimilar competition from coming to market. The Blumenthal-Cornyn legislation specifically addresses an anti-competitive tactic known as “product hopping” and an abuse of the “patent dance” process for resolving patent infringement claims for biosimilars. Companion legislation addressing abuse of the “patent dance” process is being introduced in the House of Representatives today by U.S. Representatives Hank Johnson (D-GA) and Darrell Issa (R-CA). Companion legislation prohibiting “product hopping” is…

Read More

Aliera and Trinity Healthshare Pay $50,000,

Agree to Stop Marketing in Connecticut Connecticut Insurance Commissioner Andrew N. Mais has announced that a settlement has been reached between the Connecticut Insurance Department (CID), The Aliera Companies (Aliera), and Trinity Healthshare (Trinity) over allegations that Aliera and Trinity illegally sold unlicensed insurance in Connecticut. Aliera and Trinity Healthshare, both of Atlanta, Georgia, signed a Stipulation and Consent Order on April 26 agreeing to drop their administrative appeal of a cease and desist order issued by Commissioner Mais in 2019. The firms will also pay $50,000 to the Department. The cease and desist order was issued for conducting an insurance business illegally in Connecticut and barred the companies from acting as insurers or representing insurers that are not authorized to transact insurance.  “We…

Read More